August 18, 2026
Ximena A. Levander, Ryan Cook, Devin Gregoire et al.
There has been growing public and research interest in the use of psychedelics, particularly psilocybin. There is limited data on psilocybin use patterns, motivations for use, safety, and efficacy in older adults (>or= 60 years old) as older adults tend to be excluded from clinical trials. However, older adults may seek out psilocybin through state-regulated or naturalistic settings for...
Journal of Psychoactive Drugs
March 3, 2025
Wayne Kepner, Patricia Dionicio, Katie Bailey et al.
3 citations
Little is known about ecstasy/MDMA use among Asian American and Pacific Islander populations. Research is important because AAPIs face unique cultural factors that may influence use. We estimated the prevalence and correlates of lifetime ecstasy/MDMA use based on a representative sample of US AAPI adults aged ≥18 from the 2015-2020 National Survey on Drug Use and Health. An estimated 5.1% of...
Addictive behaviors
September 1, 2022
Kevin H. Yang, Benjamin H Han, Joseph J Palamar
30 citations
There is renewed interest in the clinical application of hallucinogenic substances to treat a range of psychiatric conditions. However, there is mixed evidence regarding how use of such substances outside of medical settings relates to psychological distress, depression, and suicidality. We examined data from a US representative sample of noninstitutionalized adults from the 2015-2020 National...
Journal of Addiction Medicine
Kevin H. Yang, Wayne Kepner, Anamika Nijum et al.
11 citations
3,4-Methylenedioxymethamphetamine (MDMA) (also known as "ecstasy" or "Molly") has regained attention in recent years for its efficacy in treating posttraumatic stress disorder, and the drug was granted breakthrough therapy designation for such use by the US Food and Drug Administration in 2017. However, little is known about the current epidemiology of recreational ecstasy/MDMA use. We...